These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32478863)

  • 1. A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability.
    Efron D; Freeman JL; Cranswick N; Payne JM; Mulraney M; Prakash C; Lee KJ; Taylor K; Williams K
    Br J Clin Pharmacol; 2021 Feb; 87(2):436-446. PubMed ID: 32478863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial.
    Efron D; Taylor K; Payne JM; Freeman JL; Cranswick N; Mulraney M; Prakash C; Lee KJ; Williams K
    BMJ Open; 2020 Mar; 10(3):e034362. PubMed ID: 32152170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial.
    Beumer S; Hamers P; Oppewal A; Maes-Festen D
    BMC Psychiatry; 2021 Sep; 21(1):439. PubMed ID: 34488701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study.
    Ramerman L; de Kuijper G; Scheers T; Vink M; Vrijmoeth P; Hoekstra PJ
    J Intellect Disabil Res; 2019 May; 63(5):418-428. PubMed ID: 30609152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
    Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
    Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
    Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM;
    N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders.
    Efron D; Taylor K
    Int J Environ Res Public Health; 2023 Apr; 20(8):. PubMed ID: 37107712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
    Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
    J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Riva N; Mora G; Sorarù G; Lunetta C; Ferraro OE; Falzone Y; Leocani L; Fazio R; Comola M; Comi G;
    Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
    Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
    Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mental health needs and availability of mental health care for children and adolescents with intellectual disability in Berlin.
    Soltau B; Biedermann J; Hennicke K; Fydrich T
    J Intellect Disabil Res; 2015 Nov; 59(11):983-94. PubMed ID: 25716574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
    Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
    JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does parent management training reduce behavioural and emotional problems in children with intellectual disability? A randomised controlled trial.
    Kostulski M; Breuer D; Döpfner M
    Res Dev Disabil; 2021 Jul; 114():103958. PubMed ID: 33915381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-to-one befriending for people with intellectual disability and symptoms of depression: protocol for a pilot randomised controlled trial.
    Ali A; Mckenzie E; Hassiotis A; Priebe S; Lloyd-Evans B; Omar R; Jones R; Panca M; Fernandez V; Finning S; Moore S; O'Connor D; Roe C; King M
    BMJ Open; 2020 Jun; 10(6):e033989. PubMed ID: 32565450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
    Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot randomised controlled trial of community-led ANtipsychotic Drug REduction for Adults with Learning Disabilities.
    McNamara R; Randell E; Gillespie D; Wood F; Felce D; Romeo R; Angel L; Espinasse A; Hood K; Davies A; Meek A; Addison K; Jones G; Deslandes P; Allen D; Knapp M; Thapar A; Kerr M
    Health Technol Assess; 2017 Aug; 21(47):1-92. PubMed ID: 28857740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrence of the strengths and difficulties questionnaire and developmental behaviour checklist among children with an intellectual disability.
    Rice LJ; Emerson E; Gray KM; Howlin P; Tonge BJ; Warner GL; Einfeld SL
    J Intellect Disabil Res; 2018 Feb; 62(2):150-155. PubMed ID: 28980362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.